Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

EMEA).

One-year findings from one of two ustekinumab Phase 3 trials were presented for the first time at the annual meeting of the American Academy of Dermatology this past Saturday, February 2.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... does not sacrifice selectivity to achieve faster flow rates in comparison to nylon ... with significant open space to allow easy liquid flow while trapping particulates as ...
(Date:6/30/2015)...  The University of California, San Diego,s Center ... San Diego Extension announced their third annual workshop ... – 14, 2015, at UC San Diego (see ... intense exposure to best practices and the latest ... biologists, process engineers and business executives planning next ...
(Date:6/30/2015)... ... June 30, 2015 , ... Southern ... accepted the position of vice president of instruction at Chippewa Valley Technical College ... greatly appreciated the opportunity to lead SIUE during the past three years,” Furst-Bowe ...
(Date:6/29/2015)... 30, 2015   Pharnext SAS today announced that ... the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented ... Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress ... 27 - July 2, 2015. At Poster Viewing ... 1, 5p.m. to 7p.m. EDT: Poster 23: ...
Breaking Biology Technology:New Nanofiber Membrane Provides Fast, Efficient Filtration 2UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... Citing one-time gains due to Hurricane Katrina and other Gulf ... a net loss of nearly $45 million, or 20 cents ... information management services firm reported net income of $105.9 million, ... of 2005, a drop of 29.6 percent. , ,The decrease ...
... visit to the Menomonee Valley, Gov. Jim Doyle ... state budget for the new Wisconsin Venture Center. , ,Doyle ... that will connect entrepreneurs with sources of capital, and serve ... in Wisconsin. , ,The concept was announced in December of ...
... most spending proposals, the devil is in the details and ... Jim Doyle's new Grow Milwaukee package contains several initiatives ... ,The package, which Doyle alluded to in last week's ... economic development, healthcare, and education proposals designed to build on ...
Cached Biology Technology:Doyle proposes $2M for venture capital center 2Grow Milwaukee includes millions for tech funding 2Grow Milwaukee includes millions for tech funding 3
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a 12-year action plan calling for reducing the hypoxia zone ... and there is no evidence that nutrient loading to the ... have identified some of the biophysical and social barriers to ... that a partnership of researchers work closely with farmers to ...
... N.H. A grant to the University of New ... biologists identify an abundant yet largely unknown category of ... functions they play. The National Science Foundation awarded ... Network on eukaryotic biodiversity. The work will apply new ...
... Md. (Nov. 7, 2013)Chronic obstructive pulmonary diseasea health problem ... it progressively harder to breathecan have a dramatic effect ... activities of daily life because of the disease,s fallout ... in these muscle problems. These include loss of fitness ...
Cached Biology News:Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3UNH, UC Davis launch network to study environmental microbes 2Vitamin C could ease muscle fatigue in chronic obstructive pulmonary disease patients 2
... S-X media are neutral, porous ... exclusion chromatography of lipophilic polymers ... organic eluents. The beads are ... carbon tetrachloride, dimethylformamide, ketones, aromatics, ...
... Anti-GSTM1 Monoclonal Antibody Epitope: ... [Schistosoma japonicum]. Recommended Storage: ... Aliquot contents and freeze at -20 C ... of freezing and thawing. Centrifuge product if ...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
... unique aptamer microarray services using a ... and sequence design software to suit ... screening of aptamers as drug candidates. ... sequence design, synthesis of standard or ...
Biology Products: